Document is current

Any future updates will be listed below

Switching “Real-World” Diabetes Patients to Degludec from Other Basal Insulins Provides Different Clinical Benefits According to Their Baseline Glycemic Control

Crossref DOI link: https://doi.org/10.1007/s12325-019-00916-7

Published Online: 2019-03-16

Published Print: 2019-05-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark